82_FR_13020 82 FR 12976 - Government-Owned Inventions; Availability for Licensing

82 FR 12976 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 44 (March 8, 2017)

Page Range12976-12977
FR Document2017-04501

The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

Federal Register, Volume 82 Issue 44 (Wednesday, March 8, 2017) 
[Federal Register Volume 82, Number 44 (Wednesday, March 8, 2017)]
[Notices]
[Pages 12976-12977]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-04501]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the patent applications listed below may be obtained by communicating 
with the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

[[Page 12977]]


SUPPLEMENTARY INFORMATION: Technology description follows.

AMA1-RON2 Complex-Based Vaccine Against Malaria

Description of Technology

    This technology relates to a malaria vaccine composed of a protein 
complex of Apical Membrane Antigen (AMA1) and rhoptry neck protein 2 
(RON2) with an adjuvant. AMA1 is a crucial component of the Plasmodium 
invasion machinery and is a leading candidate for antimalarial vaccine 
development. AMA1-based vaccines have shown ability to block red cell 
invasion in in vitro assays, but protection has so far not translated 
to in vivo human infections. NIAID investigators have demonstrated that 
interaction between AMA1 and RON2 (or peptide thereof) is essential for 
malaria parasites to successfully enter human red blood cells (RBCs). 
Vaccination with un-complexed AMA1 and RON2 did not protect against 
lethal malaria. However, vaccination with a pre-formed AMA1-RON2 
complex, highlighted in this technology, produced antibodies that 
protected against lethal malaria in an in vivo mouse model (P. yoelli) 
and blocked the entry of human malaria parasites into RBCs in vitro. 
Additionally, the inhibitory antibody response induced by the AMA1-RON2 
complex was greater than AMA1 alone or when AMA1 and RON2 proteins were 
administered in a un-complexed form.
    Immunization using the AMA1-RON2 complex of this technology 
represents a candidate for an effective malaria vaccine against 
multiple Plasmodium species.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.

Potential Commercial Applications

 Malaria vaccine

Competitive Advantages

    Lower-cost malarial prevention for developing/developed countries.

Development Stage

     Early-stage.
     In vitro data available.
     In vivo data available (animal).
    Inventors: Prakash Srinivasan and Louis Miller (NIAID).
    1. Publications: Srinivasan P, et al. Binding of Plasmodium 
merozoite proteins RON2 and AMA1 triggers commitment to invasion. Proc 
Natl Acad Sci U S A. 2011 Aug 9;108(32):13275-80. [PMID 21788485].
    2. Srinivasan P, et al. Disrupting malaria parasite AMA1-RON2 
interaction with a small molecule prevents erythrocyte invasion. Nat 
Commun. 2013;4:2261. [PMID 23907321].
    Intellectual Property: HHS Reference No. E-066-2013/0--U.S. 
Provisional Application No. 61/841,479 filed 01 Jul 2013; PCT 
Application No. PCT/US2014/045065, filed July 1, 2014; European 
Application No. 14742116.8, filed July 1, 2014 (pending); U.S. 
Application No. 14/902,117, filed August December 30, 2015 (pending); 
and Chinese Application No. 201480037643.1, filed December 31, 2015 
(pending).
    Licensing Contact: Peter Tung, 240-669-5483; [email protected]. 
Collaborative Research Opportunity: The National Institute of Allergy 
and Infectious Diseases is seeking statements of capability and 
interest from parties interested in collaborative research to further 
develop, evaluate or commercialize AMA1-RON2 vaccine by providing well 
established human adjuvants and clinical trial funding. For 
collaboration opportunities, please contact Peter Tung, 240-669-5483; 
[email protected].

    Dated: February 24, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-04501 Filed 3-7-17; 8:45 am]
BILLING CODE 4140-01-P

12976 Federal Register / Vol. 82, No. 44 / Wednesday, March 8, 2017 / Notices Name of Committee: Center for Scientific Contact Person: Raymond Jacobson, Ph.D., property such as patentable material, Review Special Emphasis Panel; Member Scientific Review Officer, Center for and personal information concerning Conflict: Integrative Nutrition and Molecular Scientific Review, National Institutes of individuals associated with the contract Endocrinology. Health, 6701 Rockledge Drive, Room 5858, proposals, the disclosure of which Date: March 29, 2017. MSC 7849, Bethesda, MD 20892, 301–996– Time: 2:00 p.m. to 4:00 p.m. 7702, jacobsonrh@csr.nih.gov. would constitute a clearly unwarranted Agenda: To review and evaluate grant invasion of personal privacy. Name of Committee: Center for Scientific applications. Review Special Emphasis Panel; RFA HD– Name of Committee: National Institute of Place: National Institutes of Health, 6701 17–008: Autism Centers of Excellence: Dental and Craniofacial Research Special Rockledge Drive, Bethesda, MD 20892 Networks (R01). Emphasis Panel; NIDCR Loan Repayment (Telephone Conference Call). Date: March 31, 2017. Program SEP. Contact Person: Raul Rojas, Ph.D., Time: 8:00 a.m. to 5:00 p.m. Date: March 29–31, 2017. Scientific Review Officer, Center for Agenda: To review and evaluate grant Time: 8:00 a.m. to 5:00 p.m. Scientific Review, National Institutes of applications. Agenda: To review and evaluate contract Health, 6701 Rockledge Drive, Room 6185, Place: Embassy Suites at the Chevy Chase proposals. Bethesda, MD 20892, (301) 451–6319, rojasr@ Pavilion, 4300 Military Road NW., Place: National Institutes of Health, 6701 mail.nih.gov. Washington, DC 20015. Rockledge Drive, Bethesda, MD 20892 Name of Committee: Center for Scientific Contact Person: Jane A. Doussard- (Virtual Meeting). Review Special Emphasis Panel; PAR Panel: Roosevelt, Ph.D., Scientific Review Officer, Contact Person: Latarsha J. Carithers, Basic Research in Cancer Health Disparities/ Center for Scientific Review, National Ph.D., Scientific Review Officer, Division of Diversity. Institutes of Health, 6701 Rockledge Drive, Extramural Activities, NIDCR, 6701 Date: March 30–31, 2017. Room 3184, MSC 7848, Bethesda, MD 20892, Democracy Boulevard, Suite 672, Bethesda, Time: 8:00 a.m. to 5:00 p.m. (301) 435–4445, doussarj@csr.nih.gov. MD 20892, 301–594–4859, Agenda: To review and evaluate grant latarsha.carithers@nih.gov. Name of Committee: Center for Scientific applications. Review Special Emphasis Panel; Program (Catalogue of Federal Domestic Assistance Place: Hilton Washington/Rockville, 1750 Project: Review of Program Project. Program Nos. 93.121, Oral Diseases and Rockville Pike, Rockville, MD 20852. Date: March 31, 2017. Disorders Research, National Institutes of Contact Person: Ola Mae Zack Howard, Time: 12:00 p.m. to 4:00 p.m. Health, HHS) Ph.D., Scientific Review Officer, Center for Agenda: To review and evaluate grant Dated: March 2, 2017. Scientific Review, National Institutes of applications. Natasha M. Copeland, Health, 6701 Rockledge Drive, Room 4192, Place: National Institutes of Health, 6701 Program Analyst, Office of Federal Advisory MSC 7806, Bethesda, MD 20892, 301–451– Rockledge Drive, Bethesda, MD 20892 Committee Policy. 4467, howardz@mail.nih.gov. (Telephone Conference Call). Contact Person: Jose H. Guerrier, Ph.D., [FR Doc. 2017–04482 Filed 3–7–17; 8:45 am] Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR Panel: Scientific Review Officer, Center for BILLING CODE 4140–01–P Mycobacterial induced immunity in HIV- Scientific Review, National Institutes of infected and uninfected individuals. Health, 6701 Rockledge Drive, Room 5218, Date: March 30, 2017. MSC 7852, Bethesda, MD 20892, 301–435– DEPARTMENT OF HEALTH AND Time: 8:30 a.m. to 4:00 p.m. 1137, guerriej@csr.nih.gov. HUMAN SERVICES Agenda: To review and evaluate grant (Catalogue of Federal Domestic Assistance applications. Program Nos. 93.306, Comparative Medicine; National Institutes of Health Place: Hilton Silver Spring, 8727 Colesville 93.333, Clinical Research, 93.306, 93.333, Road, Silver Spring, MD 20910. 93.337, 93.393–93.396, 93.837–93.844, Government-Owned Inventions; Contact Person: Jingsheng Tuo, Ph.D., 93.846–93.878, 93.892, 93.893, National Availability for Licensing Scientific Review Officer, Center for Institutes of Health, HHS) Scientific Review, National Institutes of AGENCY: National Institutes of Health, Dated: March 2, 2017. HHS. Health, 6701 Rockledge Drive, Room 5207, David Clary, Bethesda, MD 20892, 301–451–8754, tuoj@ ACTION: Notice. nei.nih.gov. Program Analyst, Office of Federal Advisory Name of Committee: Center for Scientific Committee Policy. SUMMARY: The invention listed below is Review Special Emphasis Panel; RFA– [FR Doc. 2017–04484 Filed 3–7–17; 8:45 am] owned by an agency of the U.S. RM16–007: Transformative Research Award BILLING CODE 4140–01–P Government and is available for Review. licensing to achieve expeditious Date: March 31, 2017. commercialization of results of Time: 8:00 a.m. to 5:00 p.m. DEPARTMENT OF HEALTH AND federally-funded research and Agenda: To review and evaluate grant HUMAN SERVICES development. Foreign patent applications. applications are filed on selected Place: Residence Inn Bethesda, 7335 National Institutes of Health inventions to extend market coverage Wisconsin Ave., Bethesda, MD 20814. Contact Person: Raymond Jacobson, Ph.D., for companies and may also be available National Institute of Dental and for licensing. Scientific Review Officer, Center for Craniofacial Research; Notice of Scientific Review, National Institutes of FOR FURTHER INFORMATION CONTACT: Health, 6701 Rockledge Drive, Room 5858, Closed Meeting Licensing information and copies of the MSC 7849, Bethesda, MD 20892, 301–996– Pursuant to section 10(d) of the patent applications listed below may be 7702, jacobsonrh@csr.nih.gov. Federal Advisory Committee Act, as obtained by communicating with the Name of Committee: Center for Scientific amended (5 U.S.C. App.), notice is indicated licensing contact at the Review Special Emphasis Panel; RFA– hereby given of the following meeting. Technology Transfer and Intellectual mstockstill on DSK3G9T082PROD with NOTICES RM16–007: Transformative Research Award The meeting will be closed to the Property Office, National Institute of Review. public in accordance with the Allergy and Infectious Diseases, 5601 Date: March 31, 2017. Time: 8:00 a.m. to 6:00 p.m. provisions set forth in sections Fishers Lane, Rockville, MD 20852; tel. Agenda: To review and evaluate grant 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 301–496–2644. A signed Confidential applications. as amended. The contract proposals and Disclosure Agreement will be required Place: Residence Inn Bethesda, 7335 the discussions could disclose to receive copies of unpublished patent Wisconsin Avenue, Bethesda, MD 20814. confidential trade secrets or commercial applications. VerDate Sep<11>2014 17:34 Mar 07, 2017 Jkt 241001 PO 00000 Frm 00052 Fmt 4703 Sfmt 4703 E:\FR\FM\08MRN1.SGM 08MRN1

Federal Register / Vol. 82, No. 44 / Wednesday, March 8, 2017 / Notices 12977 SUPPLEMENTARY INFORMATION: Acad Sci U S A. 2011 Aug Name of Committee: Center for Scientific Technology description follows. 9;108(32):13275–80. [PMID 21788485]. Review Special Emphasis Panel; PAR–16– 2. Srinivasan P, et al. Disrupting 115: Optimization of Monoclonal Antibodies AMA1–RON2 Complex-Based Vaccine for Eliminating the HIV Reservoir. Against Malaria malaria parasite AMA1–RON2 Date: March 28, 2017. interaction with a small molecule Description of Technology Time: 10:00 a.m. to 1:00 p.m. prevents erythrocyte invasion. Nat Agenda: To review and evaluate grant This technology relates to a malaria Commun. 2013;4:2261. [PMID applications. vaccine composed of a protein complex 23907321]. Place: National Institutes of Health, 6701 of Apical Membrane Antigen (AMA1) Intellectual Property: HHS Reference Rockledge Drive, Bethesda, MD 20892. and rhoptry neck protein 2 (RON2) with No. E–066–2013/0—U.S. Provisional Contact Person: Barna Dey, Ph.D., an adjuvant. AMA1 is a crucial Application No. 61/841,479 filed 01 Jul Scientific Review Officer, Center for component of the Plasmodium invasion 2013; PCT Application No. PCT/ Scientific Review, National Institutes of machinery and is a leading candidate US2014/045065, filed July 1, 2014; Health, 6701 Rockledge Drive, Room 3184, for antimalarial vaccine development. European Application No. 14742116.8, Bethesda, MD 20892, 301–451–2796, bdey@ AMA1-based vaccines have shown filed July 1, 2014 (pending); U.S. mail.nih.gov. ability to block red cell invasion in in Application No. 14/902,117, filed Name of Committee: Center for Scientific vitro assays, but protection has so far August December 30, 2015 (pending); Review Special Emphasis Panel; PAR Panel: not translated to in vivo human and Chinese Application No. Basic Research on HIV Persistence. infections. NIAID investigators have 201480037643.1, filed December 31, Date: March 28, 2017. demonstrated that interaction between 2015 (pending). Time: 1:00 p.m. to 6:00 p.m. AMA1 and RON2 (or peptide thereof) is Licensing Contact: Peter Tung, 240– Agenda: To review and evaluate grant applications. essential for malaria parasites to 669–5483; peter.tung@nih.gov. Contact Person: National Institutes of successfully enter human red blood Collaborative Research Opportunity: Health, 6701 Rockledge Drive, Bethesda, MD cells (RBCs). Vaccination with un- The National Institute of Allergy and 20892. complexed AMA1 and RON2 did not Infectious Diseases is seeking statements Contact Person: Barna Dey, Ph.D., protect against lethal malaria. However, of capability and interest from parties Scientific Review Officer, Center for vaccination with a pre-formed AMA1– interested in collaborative research to Scientific Review, National Institutes of RON2 complex, highlighted in this further develop, evaluate or Health, 6701 Rockledge Drive, Room 3184, technology, produced antibodies that commercialize AMA1–RON2 vaccine by Bethesda, MD 20892, 301–451–2796, bdey@ protected against lethal malaria in an in providing well established human mail.nih.gov. vivo mouse model (P. yoelli) and adjuvants and clinical trial funding. For Name of Committee: Center for Scientific blocked the entry of human malaria collaboration opportunities, please Review Special Emphasis Panel; Member parasites into RBCs in vitro. contact Peter Tung, 240–669–5483; Conflict: Cancer Research. Additionally, the inhibitory antibody peter.tung@nih.gov. Date: March 29, 2017. response induced by the AMA1–RON2 Dated: February 24, 2017. Time: 11:00 a.m. to 6:00 p.m. complex was greater than AMA1 alone Suzanne Frisbie, Agenda: To review and evaluate grant or when AMA1 and RON2 proteins applications. Deputy Director, Technology Transfer and were administered in a un-complexed Intellectual Property Office, National Institute Place: National Institutes of Health, 6701 form. Rockledge Drive, Bethesda, MD 20892, of Allergy and Infectious Diseases. Immunization using the AMA1–RON2 (Telephone Conference Call). [FR Doc. 2017–04501 Filed 3–7–17; 8:45 am] complex of this technology represents a Contact Person: C–L Albert Wang, Ph.D., BILLING CODE 4140–01–P Scientific Review Officer, Center for candidate for an effective malaria vaccine against multiple Plasmodium Scientific Review, National Institutes of species. Health, 6701 Rockledge Drive, Room 4146, DEPARTMENT OF HEALTH AND MSC 7806, Bethesda, MD 20892, 301–435– This technology is available for HUMAN SERVICES 1016, wangca@csr.nih.gov. licensing for commercial development in accordance with 35 U.S.C. 209 and 37 Name of Committee: Center for Scientific National Institutes of Health CFR part 404, as well as for further Review Special Emphasis Panel; Member Center for Scientific Review; Notice of Conflict: Vaccine, Host Defense and development and evaluation under a Inflammation. research collaboration. Closed Meetings Date: March 29, 2017. Potential Commercial Applications Pursuant to section 10(d) of the Time: 3:00 p.m. to 7:00 p.m. Federal Advisory Committee Act, as Agenda: To review and evaluate grant • Malaria vaccine applications. amended (5 U.S.C. App.), notice is Competitive Advantages hereby given of the following meetings. Place: National Institutes of Health, 6705 Rockledge Drive, Bethesda, MD 20817 Lower-cost malarial prevention for The meetings will be closed to the (Telephone Conference Call). developing/developed countries. public in accordance with the Contact Person: Betty Hayden, Ph.D., provisions set forth in sections Scientific Review Officer, Center for Development Stage 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Scientific Review, National Institutes of • Early-stage. as amended. The grant applications and Health, 6701 Rockledge Drive, Room 4206, • In vitro data available. the discussions could disclose mstockstill on DSK3G9T082PROD with NOTICES MSC 7812, Bethesda, MD 20892, 301–435– • In vivo data available (animal). confidential trade secrets or commercial 1223, haydenb@csr.nih.gov. Inventors: Prakash Srinivasan and property such as patentable material, (Catalogue of Federal Domestic Assistance Louis Miller (NIAID). and personal information concerning Program Nos. 93.306, Comparative Medicine; 1. Publications: Srinivasan P, et al. individuals associated with the grant 93.333, Clinical Research, 93.306, 93.333, Binding of Plasmodium merozoite applications, the disclosure of which 93.337, 93.393–93.396, 93.837–93.844, proteins RON2 and AMA1 triggers would constitute a clearly unwarranted 93.846–93.878, 93.892, 93.893, National commitment to invasion. Proc Natl invasion of personal privacy. Institutes of Health, HHS) VerDate Sep<11>2014 17:34 Mar 07, 2017 Jkt 241001 PO 00000 Frm 00053 Fmt 4703 Sfmt 4703 E:\FR\FM\08MRN1.SGM 08MRN1


Document Created: 2017-03-08 05:07:08
Document Modified: 2017-03-08 05:07:08
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
ContactLicensing information and copies of the patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301- 496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.
FR Citation82 FR 12976 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR